ApcinteX
London
About ApcinteX
ApcinteX develops and markets anticoagulant APC pathway to treat haemophilia. Apcintex has developed a new treatment that seeks to turn down the activity of a key natural anticoagulant pathway to produce normal blood clotting in patients with haemophilia. This means that the drug could potentially treat patients with all types of haemophilia, including those who develop antibodies to replacement factors. Furthermore, the drug does not cause anti-clotting antibodies to form and could be administered fortnightly by simple injection under the skin.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $17.5M
- Funding stage: Early Stage Venture
- Last round: Series A (Feb 2017)
- Website: apcintex.com
- Phone: +44 (0) 7540 151981
Industries & Categories
Health Care, Medical, Therapeutics
Canonical: https://fsome.com/organization/apcintex-211013 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.